NCT06892756View on ClinicalTrials.gov

Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

June 20, 2025

Study Completion Date

June 20, 2025

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

CHF6001 dry powder inhaler (DPI)

CHF6001 DPI single dose administration followed by a 14 to 17-day wash-out period before Treatment Period 2

DRUG

Cyclosporine

Oral cyclosporine single dose administration

DRUG

CHF6001 DPI

CHF6001 DPI single dose administration after oral cyclosporine single dose administration

Trial Locations (1)

1612

Medical Centre Comac Medical Ltd, Sofia

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT06892756 - Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study | Biotech Hunter | Biotech Hunter